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ABSTRACT
Renal cell carcinoma (RCC) represents a challenge for clinicians since the 
nonexistence of screening and monitoring tests contributes to the fact that one-
third of patients are diagnosed with metastatic disease and 20–40% of the remaining 
patients will also develop metastasis. Modern medicine is now trying to establish 
circulating biomolecules as the gold standard of biomarkers. Among the molecules 
that can be released from tumor cells we can find microRNAs. The aim of this study 
was to evaluate the applicability of cancer-related miR-210, miR-218, miR-221 and 
miR-1233 as prognostic biomarkers for RCC. Patients with higher levels of miR-210, 
miR-221 and miR-1233 presented a higher risk of specific death by RCC and a lower 
cancer-specific survival. The addition of miR-210, miR-221 and miR-1233 plasma 
levels information improved the capacity to predict death by cancer in 8, 4% when 
compared to the current variables used by clinicians. We also verified that hypoxia 
stimulates the release of miR-210 and miR-1233 from HKC-8, RCC-FG2 and 786-O 
cell lines. These results support the addition of circulating microRNAs as prognostic 
biomarkers for RCC.
INTRODUCTION
Renal cell carcinoma (RCC) is the most common 
solid cancer of the adult kidney, accounting for 
approximately 90% of kidney neoplasms and 3% of all 
adult malignancies [1]. The most common histological 
RCC type is the clear cell RCC (ccRCC), which accounts 
for 80–90% of all RCCs. Worldwide RCC mortality 
currently exceeds 100.000 patients each year, with the 
incidence and mortality rates increasing by 2–3% per 
decade [2]. This reality and the nonexistence of screening 
and monitoring tests, contributes to the fact that one-third 
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of patients are diagnosed with metastatic disease and 20–
40% of the RCC patient’s submitted to nephrectomy will 
also develop metastasis [3]. Metastatic ccRCC remains 
incurable, but the prognosis for recurrent ccRCC varies 
widely and it has been reported that detecting early relapse 
can improve a patient’s prognosis [4].
The current gold standard of cancer diagnosis is 
the histological examination of tissue, mainly obtained 
by biopsy. However this procedure is invasive, expensive 
and present risks for the patient, which emphasizes the 
need for alternative diagnostic techniques. Liquid Biopsies 
hold great clinical promise, as their non-invasive nature 
allows for rapid, economical and multiple sampling. 
These features allow their use in screening programs 
and the close monitoring of disease progression and 
treatment response, allowing earlier intervention and a 
dynamic treatment management [5]. Among the possible 
non-invasive biomarkers that have been studied in RCC, 
the ones that seem more promising are the microRNAs 
(miRNAs), since they can be detected using non-invasive 
procedures and are easier to quantify when compared 
to other molecules [6]. MiRNAs are small (18–24 
nucleotides) non-coding RNAs that are responsible for 
the regulation of gene expression at a post-transcriptional 
level and have been widely studied in oncology since they 
are potent modulators of cellular behaviour and tumoral 
microenvironment [7, 8]. As a single miRNA may target up 
to several hundred mRNAs, aberrant miRNA expression 
may affect a multitude of transcripts and profoundly 
influence cancer-related signaling pathways [9]. MiRNAs 
are also present high stability in biofluids since they 
can be actively secreted from cells inside exosomes and 
microvesicles or circulate free in complex with proteins 
such as RNA-binding proteins, lipoproteins, high density 
lipoproteins (HDLs) and argonoute proteins [10]. The 
multitude of ways in which miRNAs can be released 
into circulation gives tumor cells the power to modulate 
the human body’s response to their own advantage [10]. 
There is evidence that miRNAs regulate the “hallmarks of 
cancer”, including the hypoxic microenvironment, a well 
established cellular characteristic of ccRCC [5]. Hypoxia is 
a unique environmental stress that induces global changes 
in a complex regulatory network of transcription factors 
and signaling pathways in order to coordinate cellular 
adaptations in metabolism, proliferation, DNA repair, 
and apoptosis [11]. One of the early molecular events 
in the oncobiology of ccRCC is the loss of von Hippel 
Lindau (VHL) gene which leads to an increase of Hypoxia 
Inducible Factor alpha (HIF-α) and, consequently, 
triggers an hypoxic response from the cell [12, 13]. 
Among the miRNAs regulated by hypoxia, we can find 
miR-210, miR-218 and miR-1233. MiR-210 expression is 
induced by hypoxia, which makes this miRNA an accurate 
indicator of the hypoxia state [14]. This miRNA is widely 
studied in cancer, including RCC, however, studies of its 
expression in biofluids are few and present contradictory 
results [15–18]. MiR-218 is considered a tumor suppressor 
miRNA in RCC and its expression is downregulated by 
hypoxia [19]. The studies regarding this miRNA were only 
performed in cell lines and tissue samples, so it would be 
interesting to evaluate its behavior in patients biofluids 
[20–23]. HIF1-α induces the transcription of multiple 
proangiogenic and growth factors including the vascular 
endothelial growth factor (VEGF) that subsequently 
activates a number of downstream pathways by binding 
mainly to VEGFR-2 [24]. MiR-221 targets VEGFR-2, 
its involved in the EGFR pathway activation and its 
overexpression in plasma samples was associated with a 
lower progression free survival (PFS) and lower overall 
survival (OS) in RCC patients by our group [25, 26]. 
MiR-1233 is considered an oncomiRNA since it targets 
p53, inhibiting its function in RCC [18]. However, so far 
there is only one study regarding miR-1233 expression in 
in RCC and, given the importance of the relation of p53 
with HIF, it is important to further study the impact of this 
miRNA in RCC progression.
Regarding circulating miRNAs in RCC, only a 
few have been suggested as potential biomarkers for 
diagnosis and/or prognosis [6, 25]. Despite promising, 
the miRNAs were studied in small cohorts and few were 
replicated by other groups, which empathizes the need for 
more studies in order to replicate, validate and establish 
circulating miRNAs as RCC biomarkers [6]. Our aim in 
this study is the evaluation of the impact of plasma levels 
of miR-210, miR-218, miR-221 and miR-1233 in clinical 
endpoints and their association with clinicopathological 
characteristics of RCC patients. 
RESULTS
MiR-210, miR-218, miR-221 and miR-1233 are 
released from tumor cell lines
To validate the hypothesis that RCC cells may 
excrete these miRNAs into circulation, we performed an 
in vitro study in which we evaluate the levels of miR-210, 
miR-218, miR-221 and miR-1233, intracellularly and 
in the culture medium, of HKC-8, RCC-FG2 and 786-
O cell lines. According to our results, with exception of 
miR-221 (Fold-change 5, P = 0.260), all the miRNAs are 
excreted from RCC-FG2 cells into their culture medium 
(Fold-change: miR-210: 3, P = 0.020; miR-218: 302, 
P = 0.002 and miR-1233: 11, P = 0.021). Regarding the 
786-O cells, all the miRNAs were also excreted to the 
medium, with exception of miR-210 that only showed a 
tendency for excretion to medium (Fold-change: miR-210: 
3, P = 0.058; miR-218: 193, P = 0.017, miR-221: 853 363, 
P < 0.001 and miR-1233: 1260, P < 0.001). Finally, none 
of the four miRNAs were excreted from HKC-8 cells 
(Fold-change: miR-210: 0.5, P = 0.744; miR-218: 7, P 
= 0.482; miR-221: 1.4, P = 0.838 and miR-1233: 4, P = 
0.327) (Figure 1). 
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Plasma levels of miR-210, miR-218, and miR-
1233 in RCC patients and their association with 
clinicopathologic characteristics
According to our results, we observed a significant 
increase in the plasma levels of miR-210, miR-218 and 
miR-1233 in RCC patients, when compared to healthy 
individuals (Fold-change: miR-210: 5, P < 0.001; miR-
218: 80, P < 0.001; and miR-1233: 52, P < 0.001) 
(Figure 2A). We did not performed this analysis for 
miR-221 because it was already made by our group in 
a previous study, were we concluded that RCC patients 
presented higher plasma levels of miR-221 [25].
However, we did not found any statistical 
differences between miR-210, miR-218 and miR-1233 
levels according to gender (miR-210: P = 0.626, miR-
218: P = 0.577 and miR-1233: P = 0.822), tumor subtype 
(miR-210: P = 0.138, miR-218: P = 0.160, miR-1233: P = 
0.132) and age (miR-210: P = 0.527, miR-218: P = 0.413, 
miR-1233: P = 0.377) in the patients group.
Regarding the clinicopathologic characteristics, 
we observed that patients with tumors larger than 7 cm 
present higher levels of miR-210 and miR-1233 (Fold-
change: miR-210: 3, P = 0.022; miR-218: 2, P = 0.249; 
miR-221: 3, P = 0.066 and miR-1233: 4, P = 0.003) 
(Figure 2D). When we compare the miRNAs expression 
levels with the Fuhrman nuclear grade, only miR-1233 
was associated with higher Fuhrman grades (Fold-change: 
miR-210: 2, P = 0.381; miR-218: 4, P = 0.051; miR-221: 
2, P = 0.246 and miR-1233: 5 P = 0.004) (Figure 2C). We 
also observed that higher levels of miR-210 and miR-1233 
were associated with presence of metastasis at the time 
of diagnosis when compared with patients with localized 
disease (Fold-change: miR-210: 3, P = 0.045; miR-218: 
0.7, P = 0.579; miR-221: 3, P = 0.030 and miR-1233 and 
miR-1233: 7, P = 0.029) (Figure 2B). 
Higher plasmatic levels of miR-210, miR-221 and 
miR-1233 and cancer-specific survival
The fifty patients in the entire cohort were separated 
into miR-210, miR-218, miR-221 and miR-1233 high risk 
(higher plasma levels) and low risk (lower plasma levels) 
groups using Cutoff Finder software (http://molpath.
charite.de/cutoff), to generate the optimum cut-off score 
for their normalized plasma expression (-ΔCq). The 
Kaplan-Meier analysis showed that patients with higher 
levels of miR-210 and miR-1233 (high risk groups) 
present a significantly lower cancer-specific survival 
(P = 0.015, P = 0.003, respectively) (Figure 3, left panel). 
MiR-218 plasma levels weren’t associated with cancer-
specific survival (P = 0.350) and miR-221 showed a 
tendency to be associated with cancer-specific survival 
(P = 0.089) Additionally, the Cutoff Finder software also 
Figure 1: Intracellular and extracellular expression of miR-210, miR-218, miR-221 miR-1233 in HKC-8, 786-O and 
RCC-FG2 cell lines. The bars represent the –ΔCq of the miRNAs plasmatic expression normalized to RNU48. (A) miR-210 levels 
in HKC-8, RCC-FG2 and 786-O cell lines and respective medium; (B) miR-218 levels in HKC-8, RCC-FG2 and 786-O cell lines and 
respective medium; (C) miR-221 levels in HKC-8, RCC-FG2 and 786-O cell lines and respective medium and (D) miR-1233 levels in 
HKC-8, RCC-FG2 and 786-O cell lines and respective medium. (Mean ± Std.Error; *P < 0.05, **P < 0.001).
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allowed us to apply a ROC analysis using the optimum 
cut-off score generated, which can be observed in Figure 
3B, 3D, 3F and 3H (right panel). Regarding miR-210, 
the sensitivity was 60.9% and the specificity was 73.1% 
(AUC = 0.70); for miR-221, the sensitivity was 71.4% 
and the specificity was 65% (AUC = 0.62) and for 
miR-1233 the sensitivity was 39.1% and the specificity 
92.6% (AUC 0.61). We also observed an addictive 
effect of the combination of the plasma levels of miR-
210, miR-221 and miR-1233. In fact, the cancer-specific 
survival was significantly lower in patients’ with higher 
levels of miR-210, miR-221 and miR-1233 (48 versus 
91 months) (Figure 4). Furthermore, multivariate Cox 
regression model using tumor TNM stage (I /II versus 
III/IV), Fuhrman nuclear grade (G1/G2 versus G3/G4), 
Age (> 60 years) and gender as co-variants, demonstrated 
a higher risk of specific death by RCC in patients who 
presented simustaneously higher levels of miR-210, mir-
221 and miR-1233 (HR = 3.02, 95%CI 1.19–7.64, P = 
0.014). The concordance (c) index was used to compare 
the predictive ability of different prognostic variables 
associated with RCC overall survival; the predictive value 
was assessed with Harrell’s concordance indexes, where 
a c index of 1 indicates perfect concordance [27]. Tumor 
TNM stage and Fuhrman nuclear grade are well-known 
prognostic factors for cancer progression. In our study, 
the predictive value of tumour TNM stage (I/II versus III/
IV), Fuhrman nuclear grade (G1/G2 versus G3/G4), and 
age (> 60 years) for poor cancer-specific survival (death 
by RCC) was 0.744 (model 1). However, this predictive 
ability increased to 0.828 (model 2) with the addition of 
the information regarding miR-210, miR-221 and miR-
1233 plasma levels. The addition of miR-210, miR-221 
and miR-1233 plasma levels information improved the 
capacity to predict death by cancer in 8.4% compared with 
model 1 (Table 1). 
Accute hypoxia exposure stimulates the release 
of miR-210 and miR-1233 from normal and 
tumor cell lines and interferes with CXCR4 
mRNA expression
In an attempt to validate the hypothesis that the 
hypoxia is involved in the release of these miRNAs into 
circulation, we stimulated all the cell lines with crescent 
doses of cobalt chloride (CoCl2), a well known hypoxia 
inducer, during 24h and evaluated its effects on miR-210 
and miR-1233 excretion in all cell lines (Figure 5). In 
normal conditions, the HKC-8 cell line doesn’t excrete 
none of the miRNAs to the cell medium. However, when 
we stimulate the cells with CoCl2, they start to excrete 
miR-210 and miR-1233 (Figure 5A–5C). Interestingly, 
when we do the same stimulus in the RCC cell lines, we 
also verify an increase of the miR-210 and miR-1233 
Figure 2: Fold-change of the plasmatic levels of miR-210, miR-218 and miR-1233 according to clinicopathological 
characteristics. The bars represent the 2-ΔΔCq as a fold-change in miRNA plasmatic expression normalized to RNU48. Expression levels 
shown are means of three technical replicates for each sample. (A) RCC patients vs healthy individuals; (B) No presence of metastasis ate 
the time of diagnosis (M0) vs Presence of metastasis at the time of diagnosis (M1); (C) Fuhrman grade G1–G2 vs Fuhrman grade G3–G4); 
and (D) Tumor ≤ 7 cm vs tumors > 7 cm. (Mean ± Std.Error; *P < 0.05, **P < 0.001).
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excretion but it’s not as accentuated as for the HKC-8 cell 
line (Figure 5D, 5E, 5G and 5H).
Additionally, we also measured the mRNA 
expression of CXCR4, a well known molecule involved in 
cancer progression and metastasis and what we observed 
was that, with the acute hypoxic stimulus, the HKC8 
cell line started to express more CXCR4 mRNA and that 
expression was dependent of the CoCl2 concentration 
(Figure 5C). However, in the 786-O cell line the CXCR4 
mRNA expression diminished with the increase of CoCl2 
concentration and in the FG-2 cell line the CXCR4 mRNA 
expression was approximately the same despite the 
increase of CoCl2 concentration (Figure 5F and 5I).
DISCUSSION
Currently, no standard approaches to biomarker 
sampling or analysis have been adopted for RCC since 
many of the potential tumor markers are still under active 
investigation for further validation [28]. There are several 
factors that must be considered when choosing miRNAs 
as candidate prognostic biomarkers for RCC. First, the 
fold-change of the miRNA should be significant enough 
to discriminate RCC patients from healthy individuals. 
Second, the biological function and carcinogenesis 
mechanism of each miRNA should be thoroughly 
investigated in RCC since a better understanding of the 
targeted genes of the miRNAs would advance their use in 
clinical settings. Last but not least, rigorous validation and 
demonstration of reproducibility in independent cohorts of 
patients are necessary to confirm the prognostic value of 
miRNAs [29]. 
Some authors state that the most miRNA enriched 
biofluid is the plasma and inclusively there is a study 
showing the superiority of plasma over serum for 
circulating miRNAs analysis [30]. This study is based 
on the release of platelets or white blood cells miRNA 
contents to the serum during the coagulation process, 
which compromise the miRNA contend in serum [30, 31]. 
The existing studies in circulating samples that evaluated 
miR-210 and miR-1233 were made in serum samples and 
miR-218 was never studied in biofluids [15–18]. Only 
miR-221 was characterized in plasma samples of RCC 
patients, in previous studies from our group [25, 32]. 
To the best of our knowledge, this is the first study that 
evaluates the plasma levels of miR-210, miR-218 and 
miR-1233 in RCC. 
Our in vitro study demonstrated that RCC-FG2 cell 
line excreted miR-210, miR-218 and miR-1233 to the 
extracellular medium and that 786-O cell line excreted 
miR-218, miR-221 and miR-1233 to the medium and 
also a tendency to excrete miR-210. Those results were 
validated in vivo when we compared plasma samples 
from RCC patients with healthy controls. Additionally we 
observed that patients with tumors higher than 7 cm and 
patients that presented metastasis at the time of diagnosis 
presented higher levels of miR-210 and miR-1233, 
suggesting that these two miRNAs are related to tumor 
aggressiveness alongside miR-221 that we previously 
reported as having higher plasma concentrations in 
RCC patients [25]. Additionally, miR-1233 was the only 
miRNA associated with higher Fuhrman grades. Although 
we didn’t find any association between miR-218 and the 
clinicalphatologic features, our results regarding this 
miRNA are interesting because it is secreted by the tumor 
cell line and its also higher in the plasma of the RCC 
patients. This suggests that miR-218 is indeed secreted 
by the tumor, but probably with a different purpose. 
Since miR-218 is described in the literature as a tumor 
suppressor miRNA and is down-regulated in RCC tumor 
samples, we hypothesize that the excretion of miR-218 is 
a mechanism that tumor cells use in order to prevent its 
tumor suppression activity [21, 22]. 
When we analyzed the individual impact of 
the expression of miR-210 and miR-1233 in clinical 
endpoints, we observed that they were both associated 
with a lower cancer-specific survival, while miR-221 
only showed a tendency towards that. Subsequently, we 
analyzed the impact of higher levels of the three miRNAs 
and we observed that patients presenting higher levels of 
miR-210, miR-221 and miR-1233 combined presented a 
higher risk of specific death by RCC and a lower cancer-
specific survival. Additionally we created a model of death 
prediction by RCC using the standard variables used in 
the clinic and compared it to a model were we added the 
expression profile of miR-210, miR-221 and miR-1233 
Table 1: Predictive models of death by RCC according to different prognostic factors
HR 95% CI P value c index
Model 1
Tumor TNM stage (I and II vs III and IV), Fuhrman nuclear grade 
(G1 and G2 vs G3 and G4), Age (> 60 years) and Gender 3.90 1.76–8.64 < 0.001 0.744
Model 2
miR-210 + miR-221 + miR-1233 plasma expression, Tumor TNM 
stage (I and II vs III and IV), Fuhrman nuclear grade (G1 and G2 
vs G3 and G4), Age (> 60 years) and Gender
3.89 1.26–12.01 0.018 0.828
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Figure 3: miR-210, miR-218, miR-221 and miR-1233 prognostic roles in patients with RCC. Cut-offs for “high” and “low” 
expression of miR-210 (A), miR-218 (C), miR-221 (E) and miR-1233 (G) were identified by the online web application Cutoff Finder. The 
optimal cut-off is defined as the point with the most significant (log-rank test) split and the effect of each miRNA in cancer-specific survival 
is presented in the corresponding Kaplan-Meier plot. The Cutoff Finder also allowed to assess the quality of the prediction through the 
construction of ROC curves using the optimal cut-off points established for miR-210 (B), miR-218 (D), miR-221 (F) and miR-1233 (H).
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and we observed that the addiction of the plasma levels of 
miR-210, miR-221 and miR-1233 improved the capacity 
to predict death by RCC in when compared to the first 
model. These results suggest that miR-210, miR-221 
and miR-1233 combined are potential prognostic profile 
of biomarkers for RCC and also open the door for the 
addition of microRNAs in predictive models of death by 
RCC. 
Additionally, we also evaluated the impact of 
acute hypoxia in the two miRNAs that presented a 
significant individual impact in cancer-specific survival: 
miR-210 and miR-1233. After the addition of crescent 
concentrations of CoCl2 to all the cell lines we observed 
that indeed hypoxia was part of the process by which 
cells excrete miRNAs into the cell medium. That effect 
is very marked in the HKC-8 cell line, were we observed 
that, in normal conditions, this cell line doesn’t excretes 
neither miR-210 nor miR-1233 but when we stimulate 
then with crescent doses of hypoxia both miRNAs are 
excreted to the cell medium. The crescent hypoxia is also 
associated with crescent production of CXCR4 mRNA, a 
potent angiogenic and tumor progression inducer. In the 
ccRCC cell lines (RCC-FG2 and 786-O) we also observe 
that the hypoxic stimulus also increases the release of 
miR-210 and miR-1233 but not as markedly as in the 
HKC-8 cell line, which may be due to the fact that 
both these cell lines already present a basal excretion 
of theses miRNAs due to their malignancy and RCC 
phenotype. Interestingly, the hypoxia stiumulus as the 
opposite effect in 786-O and RCC-FG2 cell lines when 
compared to the HKC-8 cell line, which led us to the 
conclusion that CXCR4 may only act in the first stages 
of hypoxia.
In conclusion, the stimulus to hypoxia, which 
translates in a higher grade of cell proliferation, 
angiogenesis and metastatic potential, in patients with 
higher levels of miR-210 and miR-1233 is associated 
with a lower cancer specific survival, resulting in a 
higher risk of death by RCC. For the first time it was 
demonstrated that the evaluation of the combined miR-
210, miR-221 and miR-1233 profile could allow a better 
monitorization of RCC patients’ by distinguishing poor 
from favorable risk patients. In the future it would be 
interesting to improve our RCC death prediction model 
by studying and adding more plasma miRNAs and also 
to perform more functional studies to better understand 
the effects of hypoxia on miRNA secretion from the cells. 
It would also be interesting to study the mechanism by 
which the tumor cells excreted these miRNAs since recent 
studies demonstrated that tumor cells use exosomes (small 
vesicles) to shuttle molecules from the tumor to other 
locations. 
Figure 4: Cancer-specific survival according to combined expression of miR-210, miR-221 and miR-1233 plasma levels 
in RCC patients. Patients with higher expression of miR-210, miR-221 and miR-1233 combined present a lower cancer-specific survival 




Three renal cell lines were used: HKC-8, RCC-
FG2 and 786-O. The HKC-8 cell line is an immortalized 
proximal tubular epithelial renal cell line (PTEC), the 
RCC-FG2 is a metastatic ccRCC cell line and 786-O 
is a ccRCC cell line. Both HKC-8 and RCC-FG2 were 
kindly provided by Dr Klaas Kok (Groningem University, 
Netherlands) and 786-O was kindly provided by Professor 
Carmen Jerónimo (IPO-Porto Research Center, Portugal) 
[33].
Cell culture
Initially a cryopreserved vial of each cell line 
was thawed. The RCC-FG2 and 786-O cell lines were 
maintained in RPMI 1640 (1X) medium (Gibco®), 
supplemented with 10% of FBS (Fetal Bovine Serum) 
(Gibco®) and 1% of Pen-Strep (Gibco®). The HKC-
8 cell line was kept in DMEM/F12 medium (Gibco®), 
supplemented with ITS (Insuline-transferrine-selenium) 
(Sigma-Aldrich®), Pen-Strep (Gibco®), EGF (Epidermal 
Growth Factor) (Sigma-Aldrich®), Hepes buffer (Gibco®) 
and Hydrocortisone (Sigma-Aldrich®). Both cell lines 
were maintained in a 5% CO2 incubator at 37ºC. 
When the desired confluence was achieved 
 (80–90%) the medium, in which the cells were being 
cultured, was collected for miRNA extraction and the 
cells were trypsinized, using 0.05 % trypsin-EDTA (1×) 
(Gibco®) and counted using a Neubauer chamber and 
Tripan-Blue dye (Gibco®). After counting, approximately 
two million cells were centrifuged to form a pellet for 
miRNA extraction and the remaining cells were kept in 
culture. This procedure was repeated five times for each 
cell line.
Hypoxia induction
All the cell lines were harvested during the 
logarithmic period and counted by NanoTech cell 
countes. Cell suspencions, approximately 200 000 cells/
well were seeded in 6-well plates (marca) and cultured 
Figure 5: Extracellular expression of miR-210, miR-1233 and CXCR4 in HKC-8, 786-O and RCC-FG2 cell lines after 
hypoxia induction. The bars represent the –ΔCq of miR-210, miR-1233 and CXC4 after hypoxia stimulation with crescent doses of 
CoCl2 for each cell line. (A) miR-210 levels in HKC-8 cell line after CoCl2 stimulation; (B) miR-1233 levels in HKC-8 cell line after CoCl2 
stimulation; (C) CXCR4 levels in HKC-8 cell line after CoCl2 stimulation; (D) miR-210 levels in 786-O cell line after CoCl2 stimulation; 
(E) miR-1233 levels in 786-O cell line after CoCl2 stimulation; (F) CXCR4 levels in786-O cell line after CoCl2 stimulation; (G) miR-210 
levels in RCC-FG2 cell line after CoCl2 stimulation; (H) miR-1233 levels in RCC-FG2 cell line after CoCl2 stimulation; (I) CXCR4 levels 
in RCC-FG2 cell line after CoCl2 stimulation; The –ΔCq of miR-210 and miR-1233 was normalized to RNU48 and the CXCR4 –ΔCq was 
normalized to GUSB. (Mean ± Std.Error; *P < 0.05, **P < 0.001).
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in a humidified incubator at 37ºC and 5% CO2 for 24 h. 
Then, CoCl2 (Ref C8661, Sigma-Aldrich
®), was added in 
crescent concentrations was added to each well, making 
final concentrations of 100 μM, 150 μM and 500 μM. 
The cells were incubated with CoCl2 during 24h and after 
that period the miRNAs were extracted from the cells and 
respective medium and quantified using the procedures 
previously described. This experimente was performed 
two times and in duplicate for each cell line. 
Study population
The validation of the circulating miRNA expression 
profile was made through a hospital-based study, involving 
a total of 104 individuals: 54 RCC patients and 50 healthy 
individuals. All RCC patients were Caucasian from the 
north of Portugal, with histopathologic diagnosis of RCC, 
admitted and treated at the Portuguese Oncology Institute 
of Porto (IPO-Porto) between 1 of September 2003 and 
30 of October 2013. The mean age was 60.3 ± 12.1 years, 
from which 74.1% (n = 40) were male and 25.9% (n = 
14) female. Patients’ clinical characteristics were obtained 
from their medical records. Tumor classification and 
staging were established according to the tumor-node-
metastasis (TNM) classification system of the American 
Joint Committee on Cancer (AJCC) 2010, 7ª edition 
(Table 2). For the control group, 50 healthy Caucasian 
individuals, from which 30% were male (n = 16) and 68% 
(n = 34) were female, with no history of cancer, were 
randomly recruited from the north of Portugal, with a 
mean age of 43.0 ± 15.5 years. 
Sample collection and miRNA and mRNA 
extraction/ purification 
Approximately 8 mL of peripheral blood were 
collected from all individuals through a standard method 
of intravenous collection using EDTA tubes. The blood 
tubes were centrifuged 5 minutes at 3000 rpm at room 
temperature, in order to separate the plasma fraction from 
the blood cells. 
The miRNA isolation protocol was the same for 
cultured cells, cultured cells medium and plasma samples. 
We added an acid phenol-chloroform (5:1) solution 
(Ambion®) to the samples, which, after centrifugation at 
15.000 rpm at 5ºC for 15 min, allowed the separation of 
the RNA/microRNA phase. MicroRNA purification was 
performed using the GRS microRNA kit (Grisp®), with 
adjustments in the manufactured protocol. 
The mRNA isolation and purification of the culture 
cells and cultured cell medium was performed using the 
GRS Total Blood & Cultures Cells kit (Grisp®) 
After isolation, RNA concentration and purity were 
measured at 260 and 280 nm using the NanoDrop® ND-
1000 spectrophotometer.
cDNA synthesis
The miRNA samples were used as templates for 
cDNA synthesis using a Taqman®MicroRNA Reverse 
Transcription kit (Applied Biosystems®) and sequence-
specific stem-loop primers for hsa-miR-210-3p, hsa-
miR-218-1-3p, hsa-miR-221, hsa-miR-1233-3p and 
RNU-48. We used RNU-48 as an endogenous control for 
data normalization since it presented a stable expression 
pattern among samples and was previously used for 
data normalization in RCC studies [34]. After protocol 
optimization the thermal conditions were as follows: 16ºC 
for 30 minutes, followed by 42ºC for 60 minutes and 85ºC 
for 10 minutes.
The mRNA samples served as templates for 
cDNA synthesis using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems®). The thermal 
conditions for PCR amplification were optimized to fby 
37ºC for 120 min and 85ºC for 5 min for mRNA.
Real-time PCR relative quantification 
The miRNA and mRNA expression levels were 
analyzed by quantitative real-time PCR. The reactions 
were carried out on a StepOneTMqPCR Real-Time 
PCR machine, containing 1X Master mix (Applied 
Biosystems®), with 1X probes (TaqMan® microRNA 
Expression Assays: hsa-miR-210-3p: TM000512, 
hsa-miR-218-1-3p: TM-002094, hsa-miR-221: TM-
002096, hsa-miR-1233-3p: TM-002768 and TaqMan® 
mRNA Expression Assays: CXCR4: Hs00607978_s1, 
Applied Biosystems® ), cDNA sample (≈ 50 ng), RNU-
48 endogenous control for miRNA normalization 
(TaqMan® Gene Expression Assays, TM-001006, Applied 
Biosystems®) and Human GUSB (Beta Glucoronidase) 
endogenous control (Applied Biosystems®) for mRNA 
normalization.
The amplification conditions were as follows: 
holding stage 95ºC for 20 seconds, followed by 45 cycles 
of 95ºC for 1 second and 60ºC for 20 seconds. Three 
technical replicates were made for each sample.
Data analysis was made using StepOneTM Sofware 
v2.2 (Applied Biosystems®) with the same baseline 
and threshold set for each plate, in order to generate 
quantification cycle (Cq) values for all the miRNAs in 
each sample.
Statistical analysis
Statistical analysis was also made using 
IBM®SPSS®Statistics software for Windows (Version 
22.0). The 2-ΔΔCq method, along with the Student t’ test 
were used in order to evaluate any statistical differences 
in the normalized expression levels of the miRNAs here 
explored. We used Cutoff Finder web application to 
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generate optimum cut-off point for the three deregulated 
miRNAs in the plasma samples of RCC patients. Cutoff 
Finder selects the optimum cut-off point, separating 
patients into high-risk and low-risk groups, by fitting Cox 
proportional hazard models to the dichotomized variable 
and the survival variable. The optimal cut-off is defined 
as the point with the most significant (log-rank test) 
slip [35]. A Cox porportional hazard model was used to 
analyze the patients’ cancer-specific survival, considering 
as covariants TNM stage, Fuhrman nuclear grade and age 
(> 60 years). The concordance (χ) was used to compare 
the predictive ability of the association of well-known 
prognostic variables with the combined plasma levels 
of miR-210, miR-221 and miR-1233 with χ > 0.5 being 
considered with a good prediction ability [27].
Abbreviations
RCC, Renal Cell Carcinoma; ccRCC, clear cell 
Renal Cell Carcinoma; miRNAs, microRNAs; HDL, high 
density lipoprotein; HIF-1α, Hypoxia Inducible Factor 
alpha; PTEC, proximal tubular renal cell line ; FISH, 
Fluorescence in situ Hybridization; TNM, tumor-node-
metastasis; AJCC, American Joint Committee on Cancer; 
EFNA3, ephrin A3; PTP1B, tyrosine phosphatase non-
receptor type 1; CASP8AP2, caspase 8 associated protein 
2; E2F3, E2F transcription factor 3; MNT, MAX network 
transcriptional repressor; FGFR1, fibroblast growth factor 
receptor 1; EGFR, Epidermal Growth Factor Receptor; 
VHL, von Hippel Lindau tumor suppressor; HRAS, HRas 
proto-oncogene; RASSF7, Ras association domain family 
Table 2: Distribution of the clinicopathological factors of the study population
Cases (n = 54) Control Group (n = 50 )
n % n %
Gender
Male 40 74.1 16 32
Female 14 25.9 34 68
Age
Mean ± SD 60.3 ± 12.1 43.0 ± 15.5
Histology

























member 7; RAD52, RAD52 homolog, DNA repair protein; 
BLCAP, bladder cancer associated protein.
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